BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 11319594)

  • 1. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation.
    Fried MW; Duncan A; Soroka S; Connaghan DG; Farrand A; Peter J; Strauss RM; Boyer TD; McDonald GB
    Bone Marrow Transplant; 2001 Mar; 27(6):635-9. PubMed ID: 11319594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Veno-occlusive disease of the liver].
    Rybicka M; Krysiak R; Okopień B
    Wiad Lek; 2009; 62(1):42-51. PubMed ID: 19817257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms.
    Shulman HM; Fisher LB; Schoch HG; Henne KW; McDonald GB
    Hepatology; 1994 May; 19(5):1171-81. PubMed ID: 8175139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
    Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
    Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation.
    Salat C; Holler E; Kolb HJ; Reinhardt B; Pihusch R; Wilmanns W; Hiller E
    Blood; 1997 Mar; 89(6):2184-8. PubMed ID: 9058743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation.
    Gerecitano J; Mathias C; Mick R; Duffy KM; Luger S; Stadtmauer EA; Schuster SJ; Tsai D; Nasta S; Berlin J; Phillips DK; High KA; Porter DL
    J Hematother Stem Cell Res; 2003 Apr; 12(2):215-23. PubMed ID: 12804180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.
    McDonald GB; Hinds MS; Fisher LD; Schoch HG; Wolford JL; Banaji M; Hardin BJ; Shulman HM; Clift RA
    Ann Intern Med; 1993 Feb; 118(4):255-67. PubMed ID: 8420443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M; Ringdén O
    Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers.
    Scrobohaci ML; Drouet L; Monem-Mansi A; Devergie A; Baudin B; D'Agay MF; Gluckman E
    Thromb Res; 1991 Sep; 63(5):509-19. PubMed ID: 1755004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation.
    Shulman HM; Hinterberger W
    Bone Marrow Transplant; 1992 Sep; 10(3):197-214. PubMed ID: 1422475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease of the liver.
    Oh H; Tahara T; Bouvier M; Farrand A; McDonald GB
    Bone Marrow Transplant; 1998 Oct; 22(7):675-9. PubMed ID: 9818695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
    Salat C; Holler E; Wolf C; Kolb HJ; Reinhardt B; Pihusch R; Krämling HJ; Heinemann V; Haller M; Hiller E
    Bone Marrow Transplant; 1997 Mar; 19(5):487-90. PubMed ID: 9052916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein C, protein S and antithrombin III levels in the course of bone marrow and subsequent liver transplantation due to veno-occlusive disease.
    Salat C; Holler E; Göhring P; Poley S; Kolb HJ; Pihusch R; Reinhardt B; Krämling HJ; Haller M; Hiller E
    Eur J Med Res; 1996 Nov; 1(12):571-4. PubMed ID: 9438165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in protein C, factor VII and endothelial markers after autologous bone marrow transplantation: possible implications in the pathogenesis of veno-occlusive disease.
    Bazarbachi A; Scrobohaci ML; Gisselbrecht C; Marolleau JP; Mansi A; Brice P; Gorra P; Drouet L
    Nouv Rev Fr Hematol (1978); 1993 Apr; 35(2):135-40. PubMed ID: 8332449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
    van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
    Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.
    Iguchi A; Kobayashi R; Yoshida M; Kobayashi K; Matsuo K; Kitajima I; Maruyama I
    Bone Marrow Transplant; 2001 Jun; 27(11):1173-80. PubMed ID: 11551028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
    Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
    Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
    Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.